Galectin Therapeutics (GALT) EBIT (2010 - 2026)
Galectin Therapeutics' quarterly EBIT came in at -$4.1 million in Q1 2026, up 48.37% year-on-year from -$2.7 million in Q1 2025, and down 21.16% quarter-over-quarter from -$3.4 million in Q4 2025.
Galectin Therapeutics has reported EBIT for 17 years, with the latest figure at -$4.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 48.37% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$16.3 million (up 60.02% YoY), and the FY2025 full-year result was -$20.1 million, up 52.67% from the prior year.
- EBIT for Q1 2026 stood at -$4.1 million, down from -$3.4 million in the prior quarter.
- The five-year high for EBIT was -$3.4 million in Q4 2025, with the low at -$12.4 million in Q4 2024.
- Average EBIT over 5 years is -$8.4 million, with a median of -$9.2 million recorded in 2023.
- Year-over-year, EBIT tumbled 57.27% in 2022 and jumped 72.92% in 2025.
- Tracing GALT's EBIT over 5 years: stood at -$10.6 million in 2022, then rose by 10.08% to -$9.6 million in 2023, then fell by 29.99% to -$12.4 million in 2024, then jumped by 72.92% to -$3.4 million in 2025, then declined by 21.16% to -$4.1 million in 2026.
- The last three EBIT figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.08 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | -7.90 Mn |
| Dec 31, 2024 | -12.43 Mn |
| Sep 30, 2024 | -9.07 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.17 Mn |
| Jun 30, 2023 | -9.00 Mn |
| Mar 31, 2023 | -10.34 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.12 Mn |
| Jun 30, 2022 | -9.66 Mn |
| Mar 31, 2022 | -9.94 Mn |
| Dec 31, 2021 | -7.43 Mn |
| Sep 30, 2021 | -8.24 Mn |
| Jun 30, 2021 | -8.19 Mn |
| Mar 31, 2021 | -6.32 Mn |
| Dec 31, 2020 | -7.83 Mn |
| Sep 30, 2020 | -5.93 Mn |
| Jun 30, 2020 | -6.10 Mn |
| Mar 31, 2020 | -3.58 Mn |
| Dec 31, 2019 | -5.19 Mn |
| Sep 30, 2019 | -2.86 Mn |
| Jun 30, 2019 | -3.02 Mn |
| Mar 31, 2019 | -2.37 Mn |
| Dec 31, 2018 | -2.99 Mn |
| Sep 30, 2018 | -2.68 Mn |
| Jun 30, 2018 | -3.76 Mn |
| Mar 31, 2018 | -4.18 Mn |
| Dec 31, 2017 | -2.37 Mn |
| Sep 30, 2017 | -4.41 Mn |
| Jun 30, 2017 | -4.51 Mn |
| Mar 31, 2017 | -4.95 Mn |
| Dec 31, 2016 | -4.60 Mn |
| Sep 30, 2016 | -4.54 Mn |
| Jun 30, 2016 | -5.53 Mn |
| Mar 31, 2016 | -6.81 Mn |
| Dec 31, 2015 | -4.68 Mn |
| Sep 30, 2015 | -5.90 Mn |
| Jun 30, 2015 | -4.66 Mn |
| Mar 31, 2015 | -4.84 Mn |
| Dec 31, 2014 | -3.73 Mn |
| Sep 30, 2014 | -3.48 Mn |
| Jun 30, 2014 | -3.38 Mn |
| Mar 31, 2014 | -4.84 Mn |
| Dec 31, 2013 | -2.80 Mn |
| Sep 30, 2013 | -3.55 Mn |
| Jun 30, 2013 | -2.55 Mn |
| Mar 31, 2013 | -3.21 Mn |
| Dec 31, 2012 | -2.38 Mn |
| Sep 30, 2012 | -2.90 Mn |
| Jun 30, 2012 | -2.67 Mn |
| Mar 31, 2012 | -1.95 Mn |
| Dec 31, 2011 | -3.37 Mn |
| Sep 30, 2011 | -2.03 Mn |
| Jun 30, 2011 | -2.99 Mn |
| Mar 31, 2011 | -2.01 Mn |
| Dec 31, 2010 | -1.29 Mn |
| Sep 30, 2010 | -1.21 Mn |
| Jun 30, 2010 | -1.35 Mn |